Pharmacy and Poisons Board

Pharmacy and Poisons Board

Ensuring Safety, Quality and Efficacy of Medicines

Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 40, showing 5 Applications out of 200 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/14/06/02  
    Evaluation of the effectiveness, acceptability, and palatability of Air Classified Calcium Silicate (ACCS100) clay to reduce aflatoxin exposure in a high-risk community in Kenya   
Principal Investigator(s)
1. John M Vulule
Site(s) in Kenya
Makindu sub county level four hospital,
 
Trial Status completed
Protocol Date 07-04-2014
View

2.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
Trial Status not yet recruiting
Protocol Date 18-12-2015
View

3.

ECCT/11/04/01  
    A Double-blind, Randomized Trial of Monthly Treatment with Metronidazole and Miconazole Co-formulated Suppositories versus Placebo for Preventing Vaginal Infections in HIVSeronegative Women (DMID Protocol Number: 09-0070)   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Kenya AIDS Vaccine Initiative (Nairobi City county)
2. Kenya AIDS Control Program (Nairobi City county)
3. Mombasa HIV/STD Research Clinic (Mombasa county)
 
Trial Status Analysing
Protocol Date 29-07-2010
View

4.

ECCT/17/08/03   Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.           
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI Siaya
 
Trial Status recruiting
Protocol Date 14-02-2017
View

5.

ECCT/15/11/01   A5264
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy   versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of   Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Dr. Victor Otieno Mudhune
Site(s) in Kenya
1. KEMRI CDC (Kisumu county)
 
Trial Status stopped
Protocol Date 04-08-2010
View